Business Description
Intra-Cellular Therapies Inc
NAICS : 325412
SIC : 2834
ISIN : BRI2TCBDR009
Share Class Description:
BSP:I2TC34: BRDRCompare
Compare
Traded in other countries / regions
ITCI.USA23I.GermanyI2TC34.BrazilITCI.Mexico IPO Date
2023-07-24Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 29.4 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 29.63 | |||||
| Beneish M-Score | 220.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 147 | |||||
| 3-Year EBITDA Growth Rate | 20.3 | |||||
| 3-Year EPS without NRI Growth Rate | 23.3 | |||||
| 3-Year FCF Growth Rate | 26.5 | |||||
| 3-Year Book Growth Rate | -9.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 291.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 42.31 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 100 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.41 | |||||
| Quick Ratio | 5.31 | |||||
| Cash Ratio | 4.03 | |||||
| Days Inventory | 321.87 | |||||
| Days Sales Outstanding | 74.14 | |||||
| Days Payable | 105.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | 0.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.7 | |||||
| Operating Margin % | -34.49 | |||||
| Net Margin % | -30.22 | |||||
| FCF Margin % | -27.31 | |||||
| ROE % | -22.65 | |||||
| ROA % | -19.2 | |||||
| ROIC % | -122.51 | |||||
| ROC (Joel Greenblatt) % | -161.6 | |||||
| ROCE % | -25.26 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.28 | |||||
| PB Ratio | 11.21 | |||||
| Price-to-Tangible-Book | 11.21 | |||||
| EV-to-EBIT | -42.55 | |||||
| EV-to-Forward-EBIT | -32.72 | |||||
| EV-to-EBITDA | -42.7 | |||||
| EV-to-Forward-EBITDA | -71.57 | |||||
| EV-to-Revenue | 14.67 | |||||
| EV-to-Forward-Revenue | 5.67 | |||||
| EV-to-FCF | -54.61 | |||||
| Price-to-Net-Current-Asset-Value | 12.48 | |||||
| Price-to-Net-Cash | 18.34 | |||||
| Earnings Yield (Greenblatt) % | -2.35 | |||||
| FCF Yield % | -1.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intra-Cellular Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 2,293.635 | ||
| EPS (TTM) (R$) | -7.285 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (R$) | 0.000007 | ||
| 20-Day SMA (R$) | 49.53 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (R$) | 48.74 - 49.53 | ||
| Shares Outstanding (Mil) | 105.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intra-Cellular Therapies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intra-Cellular Therapies Inc Stock Events
| Event | Date | Price(R$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intra-Cellular Therapies Inc Frequently Asked Questions
What is Intra-Cellular Therapies Inc(BSP:I2TC34)'s stock price today?
The current price of BSP:I2TC34 is R$49.53. The 52 week high of BSP:I2TC34 is R$49.53 and 52 week low is R$48.74.
When is next earnings date of Intra-Cellular Therapies Inc(BSP:I2TC34)?
The next earnings date of Intra-Cellular Therapies Inc(BSP:I2TC34) is 2024-05-07.
Does Intra-Cellular Therapies Inc(BSP:I2TC34) pay dividends? If so, how much?
Intra-Cellular Therapies Inc(BSP:I2TC34) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers